Many people living with focal onset seizures (FOS) fail to achieve seizure freedom, even after taking two or more ...

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Founded in 1995 by Israeli pediatric cardiologist Dr. Ami Cohen, Save a Child’s Heart (SACH) is one of Israel’s most ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

It was the first time in nearly a year that hearings in the case had been convened, with a new judge presiding. Khalid Shaikh ...

The European Broadcasting Union (EBU), France Télévisions and Cartoon have announced a new collaborative animation production project, developed for young audiences across Europe. Following a ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) ...

The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell ...

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

Background Patients and families from culturally and linguistically diverse (CALD) backgrounds face distinct challenges ...

Roza’s case was prioritised due to the complexity of her condition, as assessments indicated a need for advanced treatment of ...